Berenguer J, Carrasco D. Double-blind trial of silymarin vs. placebo in the treatment of chronic hepatitis.
Munch Med Wochenschr.
1977;119:240-260.
Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB 1016) in chronic active hepatitis.
Int J Clin Pharmacol Ther Toxicol.
1993;31:456-460.
Lirussi F, Okolicsanyi L. Cytoprotection in the nineties: experience with ursodeoxycholic acid and silymarin in chronic liver disease.
Acta Physiol Hung.
1992;80:363-367.
Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres [translated from German].
Med Klin.
1978;73:1060-1065.
Bode JC, Schmidt U, Durr HK. Silymarin for the treatment of acute viral hepatitis? Report of a controlled trial [translated from German].
Med Klin.
1977;72:513-518.
Magliulo E, Gagliardi B, Fiori GP. Results of a double blind study on the effect of silymarin in the treatment of acute viral hepatitis, carried out at two medical centres [translated from German].
Med Klin.
1978;73:1060-1065.
Schulz V, Hansel R, Tyler VE.
Rational Phytotherapy: A Physicians' Guide to Herbal Medicine
3rd ed. Berlin, Germany: Springer-Verlag; 1998:216.
Hikino H, Kiso Y. Natural products for liver disease.
Econ Med Plant Res.
1988;2:39-72.
Muzes G, Deak G, Lang I, et al. Effects of silymarin (Legalon) therapy on the antioxidant defense mechanism and lipid peroxidation in alcoholic liver disease [in Hungarian].
Orv Hetil.
1990;131:863-866.
Lorenz D, Lucker PW, Mennicke WH, et al. Pharmacokinetic studies with silymarin in human serum and bile.
Methods Find Exp Clin Pharmacol.
1984;6:655-661.
Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin.
Hepatology.
1996;23:749-754.
Comoglio A, Tomasi A, Malandrino S, et al. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals.
Biochem Pharmacol.
1995;50:1313-1316.
Arase Y, Ikeda K, Murashima N, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients.
Cancer.
1997;79:1494-1500.
Liu JP, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B (Cochrane Review).
Cochrane Database Syst Rev.
2001;1-27, +7 tables.
Civeira MP, Castilla A, Morte S, et al. A pilot study of thymus extract in chronic non-A, non-B hepatitis.
Aliment Pharmacol Ther.
1989;3:395-401.
Bortolotti F, Cadrobbi P, Crivellaro C, et al. Effect of an orally administered thymic derivative, thymomodulin, in chronic type B hepatitis in children.
Curr Ther Res.
1988;43:67-72.
Galli M, Crocchiolo P, Negri C, et al. Attempt to treat acute type B hepatitis with an orally administered thymic extract (thymomodulin): preliminary results.
Drugs Exp Clin Res.
1985;11:665-669.
Raymond RS, Fallon MB, Abrams GA. Oral thymic extract for chronic hepatitis C in patients previously treated with interferon. A randomized, double-blind, placebo-controlled trial.
Ann Intern Med.
1998;129:797-800.
Berk L, de Man RA, Schalm SW, et al. Beneficial effects of
Phyllanthus amaru
s for chronic hepatitis B.
J Hepatol.
1991;12:405-406.
Calixto JB, Santos AR, Cechinel Filho V, et al. A review of the plants of the genus
Phyllanthus: their chemistry, pharmacology, and therapeutic potential.
Med Res Rev.
1998;18:225-258.
Leelarasamee A, Trakulsomboon S, Maunwongyathi P, et al. Failure of
Phyllanthus amarus
to eradicate hepatitis B surface antigen from symptomless carriers.
Lancet.
1990;335:1600-1601.
Thyagarajan SP, Jayaram S, Valliammai T, et al.
Phyllanthus amarus
and hepatitis B.
Lancet.
1990;336:949-950.
Thamlikitkul V, Wasuwat S, Kanchanapee P. Efficacy of
Phyllanthus amarus
for eradication of hepatitis B virus in chronic carriers.
J Med Assoc Thai.
1991;74:381-385.
Doshi JC, Vaidya AB, Antarkar DS, et al. A two-stage clinical trial of
Phyllanthus amarus
in hepatitis B carriers: failure to eradicate the surface antigen.
Indian J Gastroenterol.
1994;13:7-8.
Milne A, Hopkirk N, Lucas CR, et al. Failure of New Zealand hepatitis B carriers to respond to
Phyllanthus amarus.Med J.
1994;107:243.
Narendranathan M, Remla A, Mini PC, et al. A trial of
Phyllanthus amarus
in acute viral hepatitis.
Trop Gastroenterol.
1999;20:164-166.
Wang M, Cheng H, Li Y, et al. Herbs of the genus phyllanthus in the treatment of chronic hepatitis B: observation with three preparations from different geographic sites.
J Lab Clin Med.
1995;126:350-352.
Thyagarajan SP, Subramanian S, Thirunalasundar T, et al. Effect of
Phyllanthus amarus
on chronic carriers of hepatitis B virus.
Lancet.
1988;2:764-766.
Japanese Health Ministry confirms effectiveness of Tsumura's top-selling kampo herbal prescription.
Kampo Today [serial online].
1995;1. Available at:
http://www.tsumura.co.jp/english/kthp/1-2-01.htm. Accessed November 4, 2002.
Hirayama C, Okumura M, Tanikawa K, et al. A multicenter randomized controlled clinical trial of Shosaiko-to in chronic active hepatitis.
Gastroenterol Jpn.
1989;24:715-719.
McCulloch M, Broffman M, Gao J, et al. Chinese herbal medicine and interferon in the treatment of chronic hepatitis B: a meta-analysis of randomized, controlled trials.
Am J Public Health.
2002;92:1619-1628.
Liu JP, McIntosh H, Lin H. Chinese medicinal herbs for asymptomatic carriers of hepatitis B virus infection.
Cochrane Database Syst Rev.
2001;CD002231.
Liu JP, Manheimer E, Tsutani K, et al. Medicinal herbs for hepatitis C virus infection.
Cochrane Database Syst Rev.
2001;CD003183.
Liu JP, McIntosh H, Lin H. Chinese medicinal herbs for chronic hepatitis B.
Cochrane Database Syst Rev.
2001;CD001940.
Verucchi G, Calza L, Attard L, et al. Acute hepatitis induced by traditional Chinese herbs used in the treatment of psoriasis.
J Gastroenterol Hepatol.
2002;17:1342-1345.
Das DG. A double-blind clinical trial of kamalahar, an indigenous compound preparation, in acute viral hepatitis.
Indian J Gastroenterol.
1993;12:126-128.
Saxena S, Garg AK, Jain A. Liv.52 in infective hepatitis. A study of Liv.52 therapy in infective hepatitis in children.
Current Medical Practice.
1980;5:194.
Sama SK, Krishnamurthy L, Ramachandran K, et al. Efficacy of Liv.52 in acute viral hepatitis. A double-blind study.
Indian J Med Res.
1976;5:738.
Mendal JN, Roy BK. Studies with Liv.52 in the treatment of infective hepatitis, chronic active hepatitis and cirrhosis of the liver.
Probe.
1983;22:217.
Vaidya AB, Antarkar DS, Doshi JC, et al.
Picrorhiza kurroa
(Kutaki) Royle ex Benth as a hepatoprotective agent—experimental & clinical studies.
J Postgrad Med.
1996;42:105-108.
Frezza M, Surrenti C, Manzillo G, et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study.
Gastroenterology.
1990;99:211-215.
Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.
Hepatogastroenterology.
1998;45:797-804.
Guan R, Ho KY, Kang JY, et al. The effect of polyunsaturated phosphatidyl choline in the treatment of acute viral hepatitis.
Aliment Pharmacol Ther.
1995;9:699-703.
European Scientific Cooperative on Phytotherapy.
Valerianae radix.
Exeter, UK: ESCOP; 1996-1997:2. Monographs on the Medicinal Uses of Plant Drugs, Fascicule 4.
Chan TY, Tang CH, Critchley JA. Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian).
Postgrad Med J.
1995;71:227-228.
Chan TY. An assessment of the delayed effects associated with valerian overdose [letter].
Int
J Clin Pharmacol Ther.
1998;36:569.
Jakkula M, Boucher TA, Beyendorff U, et al. A randomized trial of Chinese herbal medicines for the treatment of symptomatic hepatitis C.
Arch Intern Med.
2004;164:1341-1346.
Liu J, Zhu M, Shi R, Yang M. Radix
Sophorae flavescentis
for chronic hepatitis B: a systematic review of randomized trials.
Am J Chin Med.
2003;31:337-354.
Chan HL, Sung JJ, Fong WF, et al. Double-blinded placebo-controlled study of
Phyllanthus urinaris
for the treatment of chronic hepatitis B.
Aliment Pharmacol Ther.
2003;18:339-345.
Gunduz H, Karabay O, Tamer A, et al. N-acetylcysteine therapy in acute viral hepatitis.
World J Gastroenterol.
2003;9:2698-700.
Gordon A, Hobbs DA, Bowden DS, et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C.
J Gastroenterol Hepatol.
2006;21:275-280.
Mollison L, Totten L, Flexman J, et al. Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C.
J Gastroenterol Hepatol.
2006;21:1184-1188.
Groenbaek K, Friis H, Hansen M, et al. The effect of antioxidant supplementation on hepatitis C viral load, transaminases and oxidative status: a randomized trial among chronic hepatitis C virus-infected patients.
Eur J Gastroenterol Hepatol.
2006;18:985-989.
Orlent H, Hansen BE, Willems M, et al. Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial.
J Hepatol.
2006 Jun 30. [Epub ahead of print]
Torres M, Rodriguez-Serrano F, Rosario DJ, et al. Does Silybum marianum play a role in the treatment of chronic hepatitis C?
PR Health Sci J.
2006;23:69-74
Yuen MF, Tam S, Fung J, et al. Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study.
Aliment Pharmacol Ther.
2006;24:1179-86
Vaidya AB, Antarkar DS, Doshi JC, et al. Picrorhiza kurroa (Kutaki) Royle ex Benth as a hepatoprotective agent--experimental & clinical studies.
J Postgrad Med.
1996;42:105-108.
Rambaldi A, Jacobs B, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases.
Cochrane Database Syst Rev.
2007;CD003620.
Saller R, Brignoli R, Melzer J, et al. An updated systematic review with meta-analysis for the clinical evidence of silymarin.
Forsch Komplement Med.
2008;15:9-20.
Andreone P, Gramonzi A, Bernardi M.
Vitamin E for chronic hepatitis B.
Ann Intern Med.
1998;128(2):156-157.
Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C.
Meta-analysis: antioxidant supplements for liver diseases - the Cochrane Hepato-Biliary Group.
Aliment Pharmacol Ther.
2010;32(3):356-367.
El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis.
Phytomedicine.
2009;16(5):391-400.
Liu1 J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection.
Cochrane Library.
2001:CD003183.
Zhao S, Liu E, Wei K, et al. Interferon plus Chinese herbs are associated with higher sustained virological response than interferon alone in chronic Hepatitis C: a meta-analysis of randomised trials.
Antiviral Res.
2011;89(2):156-164.
El-Kamary SS, Shardell MD, Abdel-Hamid M, et al. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis.
Phytomedicine.
2009;16(5):391-400.
Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection.
Cochrane Database Syst Rev.
2011 Apr 13;4:CD008960.
Last reviewed July 2012 by EBSCO CAM Review Board
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.